Impact of setting distinct target blood glucose levels on endogenous insulin suppression and pharmacodynamics of insulin preparations  

作　　者：Hui Liu Ting Li Xin-Lei Chen Hong-Ling Yu Ye-Rong Yu 

机构地区：[1]Department of Endocrinology and Metabolism,West China Hospital of Sichuan University,Chengdu 610041,Sichuan Province,China [2]Clinical Trial Center,West China Hospital of Sichuan University,Chengdu 610041,Sichuan Province,China [3]Health Management Center,General Practice Medical Center,West China Hospital of Sichuan University,Chengdu 610041,Sichuan Province,China

出　　处：《World Journal of Diabetes》2025年第2期47-54,共8页世界糖尿病杂志(英文)

基　　金：This retrospective analysis incorporated data from two clinical trials(CTR20220854 and CTR20222843);sponsored by Chongqing Chenan Biopharmaceutical Co.,Ltd.and Jiangsu Hengrui Pharmaceuticals Co.,Ltd.However,these sponsors did not partake in the study design,data interpretation,or manuscript preparation.

摘　　要：BACKGROUND Insulin therapy plays a crucial role in managing diabetes.Regulatory guidelines mandate assessing the pharmacokinetics(PK)and pharmacodynamics(PD)of new insulin formulations with euglycemic clamp techniques before entry into the market.Typically,blood glucose(BG)levels are maintained at 5%below baseline to suppress endogenous insulin secretion in healthy volunteers.However,in scenarios where BG baseline is relatively low,maintaining it at 5%below baseline can increase hypoglycemic risk.Consequently,we adjusted to maintain it at 2.5%below a baseline of<4.00 mmol/L.It remains uncertain whether this adjustment impacts endogenous insulin inhibition or the PD of study insulin.AIM To evaluate and compare the PD and C-peptide status using two different target BG setting methods.METHODS Data came from euglycemic clamp trials assessing the PK/PD of insulin aspart(IAsp)in healthy participants.Target BG was set at 2.5%below baseline for those with a basal BG of<4.00 mmol/L(group A),and at 5%below baseline for others(group B).The area under the curve(AUC)of IAsp(AUC_(IAsp,0-8 h))and GIR from 0 to 8 hours(AUCGIR,0-8 h)was used to characterize the PK and PD of IAsp,respectively.The C-peptide reduction and PK/PD of IAsp were compared between the two groups.RESULTS Out of 135 subjects,15 were assigned to group A and 120 to group B;however,group B exhibited higher basal Cpeptide(1.59±0.36 vs 1.32±0.42 ng/mL,P=0.006).Following propensity score matching to adjust for basal Cpeptide differences,71 subjects(15 in group A and 56 in group B)were analyzed.No significant differences were observed in demographics,IAsp dosage,or clamp quality.Group B showed significantly higher baseline(4.35±0.21 vs 3.91±0.09 mmol/L,P<0.001),target(4.13±0.20 vs 3.81±0.08 mmol/L,P<0.001),and clamped(4.10±0.17 vs 3.80±0.06 mmol/L,P<0.001)BG levels.Both groups exhibited comparable C-peptide suppression(32.5%±10.0%vs 35.6%±12.1%,P=0.370)and similar IAsp activity(AUCGIR,0-8 h:1433±400 vs 1440±397 mg/kg,P=0.952)under nearly equivalent IAsp

关 键 词：Euglycemic clamp Target glucose setting Healthy subject C-PEPTIDE PHARMACODYNAMICS Endogenous insulin secretion 

分 类 号：R587.1[医药卫生—内分泌]